Why the study?
Many cardiovascular biomarkers lack evidence-based effectiveness and prognostic value, while cardiospecific autoantibodies may offer advantages for diagnosing myocyte cell damage.
Do serum autoantibodies to cTnI, ACTC1, and MUN7B have diagnostic value in patients with cardiac pathology?
Do serum autoantibodies to cTnI, ACTC1, and MUN7B have diagnostic value in patients with cardiac pathology?
Elevated levels of autoantibodies to cTnI, ACTC1, and MUN7B correlate with traditional markers of necrosis and ischemia, suggesting their potential as diagnostic biomarkers for cardiac pathology.
No takes yet. Share an insight, caveat, or question.
May support diagnostic biomarker potential in cardiac pathology; leaves open clinical utility pending prospective validation.
Elvira D. Lovochkina (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: